Paper2644532
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
Fisher B and 9 others. N Engl J Med, 1989. Cited by 1,326 papers, by iCite.
Cite this record
ConductScience Library. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. Papers, record 2644532. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2644532
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
- PubMed
- Publication types
- Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Lymph Nodes | Major topic |
| Receptors, Estrogen | Major topic |
| Tamoxifen | Major topic |
| Adult | |
| Aged | |
| Analysis of Variance | |
| Clinical Trials as Topic | |
| Combined Modality Therapy | |
| Double-Blind Method | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Lymphatic Metastasis | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Postoperative Care | |
| Random Allocation | |
| Receptors, Progesterone |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| U10-CA-12027 | NCI NIH HHS | United States | U10CA012027 | PubMed and NIH |
Source NIH RePORTER
Cited by293
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,326 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42804883 | Performance of large language models in ambiguous treatment scenarios of early breast cancer. | Breast | 2026 | https://conductscience.org/library/papers/42804883 | PubMed |
| 42290019 | Oncotype DX: Clinical Utility, Evidence, and Future Trends in Personalized Breast Cancer Management. | Int J Cancer | 2026 | https://conductscience.org/library/papers/42290019 | PubMed |
| 42157433 | Multidimensional Cellular Micro-Compartments to Model Invasive Lobular Carcinoma Dormancy. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42157433 | PubMed |
| 41634433 | Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41634433 | PubMed |
| 41559081 | Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice. | Nat Commun | 2026 | https://conductscience.org/library/papers/41559081 | PubMed |
| 41398127 | Physician Partnerships and Adverse Outcomes among Breast Cancer Survivors: The Role of Adherence to Adjuvant Hormone Therapy. | J Gen Intern Med | 2026 | https://conductscience.org/library/papers/41398127 | PubMed |
| 40275985 | Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. | Oncol Rev | 2025 | https://conductscience.org/library/papers/40275985 | PubMed |
| 40099018 | Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer. | Biologics | 2025 | https://conductscience.org/library/papers/40099018 | PubMed |
| 39144911 | An Unusual Occurrence of Tamoxifen-Induced Maculopathy in a Young Woman With Hormone Receptor-Positive Post-mastectomy Breast Carcinoma. | Cureus | 2024 | https://conductscience.org/library/papers/39144911 | PubMed |
| 38291801 | Prolonged tamoxifen-enriched diet is associated with cardiomyopathy and nutritional frailty in mice. | Exp Physiol | 2024 | https://conductscience.org/library/papers/38291801 | PubMed |
| 38116321 | Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/38116321 | PubMed |
| 38097623 | Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/38097623 | PubMed |
| 37783846 | Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. | Nat Rev Endocrinol | 2024 | https://conductscience.org/library/papers/37783846 | PubMed |
| 37583424 | Targeting nuclear hormone receptors for the prevention of breast cancer. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37583424 | PubMed |
| 37380659 | Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/37380659 | PubMed |
| 37290594 | Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma. | Biochem Pharmacol | 2023 | https://conductscience.org/library/papers/37290594 | PubMed |
| 36987503 | Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk. | Breast Cancer (Dove Med Press) | 2023 | https://conductscience.org/library/papers/36987503 | PubMed |
| 36755288 | Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer. | Cancer Metab | 2023 | https://conductscience.org/library/papers/36755288 | PubMed |
| 35642027 | The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation. | BMC Pharmacol Toxicol | 2022 | https://conductscience.org/library/papers/35642027 | PubMed |
| 35550274 | Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35550274 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2644532
GET https://conductscience.org/api/papers/v1/2644532/cited_by?page=2